Shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) last traded at $6.92. (NASDAQ:GLMD) performance year to date is 97.15%. The 200 day simple moving average is 60.28%. The 200 SMA is considered a major indicator by market analysts and traders for determining the long-term trend. The price in the market that coincides with the 200 day SMA is recognized as a key support when price moves above the 200 day SMA or resistance when price drops below the same.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has been in the buzz for all the right reasons.
The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions. Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend. The market is in highly overbought territory. Beware of a trend reversal.
The Exponential Moving Average is similar to a simple moving average but it uses a weighting element that exponentially drops from the recent data point. EMA analysis assesses the short term,5 days and 13 days, intermediate term that is 20 days and long-term 50 days EMA. These EMAs will give bullish indications when moving above trailing EMAs and below the latest price and vice versa. EMA alerts comprise crossovers that is the 5 day EMA crosses below/above the 20 day EMA and EMA convergences, 5 day EMA comparable to 13 day EMA. The long term and short term EMA’s of 6.02 and 5.07 are lower than the current trading price suggesting a bullish pattern in both short term as well as long term. .
The relative strength index is a momentum oscillator that can measure the magnitude of stock price and velocity changes. Momentum is computed as the ratio of plus price changes to negative price changes. The RSI assessment compares the prevailing RSI against oversold (30), overbought (70) and neutral (50) conditions. Alerts will apprise you when stocks retreat from overbought/oversold levels or breakthrough neutral (50). The current RSI is 84.23 suggesting a bullish price action.
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) is all set to report its earnings on May 15/b. As per Zack’s analyst scores, Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) currently has a mean brokerage rating of . On a scale of 1-5, a rating of 1 or 2 would imply a buy, and a rating of 4 or 5 would indicate a sell recommendation. A rating of 3 would represent a hold on the equity. The consensus target price on (NASDAQ:GLMD) is $ with a high of $ and a low of $.
As such, while we consider Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) represents a enthralling growth story open to several attractive markets, it would be fascinating to see how it works for long-term shareholders.